KR20170109582A - 벡터 공동 발현 백신 및 공동 자극 분자 - Google Patents

벡터 공동 발현 백신 및 공동 자극 분자 Download PDF

Info

Publication number
KR20170109582A
KR20170109582A KR1020177022218A KR20177022218A KR20170109582A KR 20170109582 A KR20170109582 A KR 20170109582A KR 1020177022218 A KR1020177022218 A KR 1020177022218A KR 20177022218 A KR20177022218 A KR 20177022218A KR 20170109582 A KR20170109582 A KR 20170109582A
Authority
KR
South Korea
Prior art keywords
cell
leu
ser
val
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177022218A
Other languages
English (en)
Korean (ko)
Inventor
테일러 슈라이버
조지 프롬
Original Assignee
히트 바이오로직스, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 히트 바이오로직스, 인코퍼레이티드 filed Critical 히트 바이오로직스, 인코퍼레이티드
Publication of KR20170109582A publication Critical patent/KR20170109582A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
KR1020177022218A 2015-02-06 2016-02-05 벡터 공동 발현 백신 및 공동 자극 분자 Ceased KR20170109582A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562113153P 2015-02-06 2015-02-06
US62/113,153 2015-02-06
US201562174942P 2015-06-12 2015-06-12
US62/174,942 2015-06-12
PCT/US2016/016682 WO2016127015A1 (en) 2015-02-06 2016-02-05 Vector co-expressing vaccine and costimulatory molecules

Publications (1)

Publication Number Publication Date
KR20170109582A true KR20170109582A (ko) 2017-09-29

Family

ID=56564722

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177022218A Ceased KR20170109582A (ko) 2015-02-06 2016-02-05 벡터 공동 발현 백신 및 공동 자극 분자

Country Status (15)

Country Link
US (4) US10046047B2 (enExample)
EP (1) EP3253876B1 (enExample)
JP (1) JP6744318B2 (enExample)
KR (1) KR20170109582A (enExample)
CN (1) CN107208099B (enExample)
AU (1) AU2016215175B2 (enExample)
BR (1) BR112017016681A2 (enExample)
CA (1) CA2975191C (enExample)
DK (1) DK3253876T3 (enExample)
ES (1) ES2845727T3 (enExample)
IL (1) IL253423B (enExample)
MX (1) MX384422B (enExample)
RU (1) RU2714157C2 (enExample)
SG (1) SG11201705844SA (enExample)
WO (1) WO2016127015A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201705844SA (en) * 2015-02-06 2017-08-30 Heat Biologics Inc Vector co-expressing vaccine and costimulatory molecules
CN107708725A (zh) * 2015-04-02 2018-02-16 坎库雷有限公司 用于引发免疫应答的剂和组合物
CN116063566A (zh) 2015-10-01 2023-05-05 热生物制品有限公司 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法
EP3515486A4 (en) * 2016-09-26 2020-05-20 Advantagene, Inc. METHOD FOR TREATING TIM-3 INCREASE
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
EP3577133A1 (en) 2017-02-06 2019-12-11 Orionis Biosciences NV Targeted chimeric proteins and uses thereof
CN110381974A (zh) * 2017-02-27 2019-10-25 沙塔克实验室有限公司 基于csf1r的嵌合蛋白
CN110234345A (zh) 2017-02-27 2019-09-13 沙塔克实验室有限公司 制备和使用基于细胞外结构域的嵌合蛋白的方法
US11192933B2 (en) * 2017-02-27 2021-12-07 Shattuck Labs, Inc. VSIG8-based chimeric proteins
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
WO2019104327A1 (en) * 2017-11-27 2019-05-31 Heat Biologics, Inc. Gp96-based cancer therapy
EP3720450A4 (en) * 2017-12-04 2021-07-28 Heat Biologics, Inc. CELL-BASED VACCINE PRODUCTION
US12084497B2 (en) 2018-08-08 2024-09-10 Orionis Biosciences, Inc. SIRP1α targeted chimeric proteins and uses thereof
CN112888706A (zh) * 2018-08-29 2021-06-01 沙塔克实验室有限公司 包含基于tim-3的嵌合蛋白的组合疗法
WO2020047319A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Combination therapies comprising sirp alpha-based chimeric proteins
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
EP3860647A4 (en) * 2018-10-01 2022-10-19 Heat Biologics, Inc. CELL-BASED COMBINATION THERAPIES
WO2020106621A1 (en) * 2018-11-19 2020-05-28 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
EP4021494A1 (en) * 2019-08-30 2022-07-06 Pelican Therapeutics, Inc. Methods of treating cancer using tnfrsf25 antibodies
US20210283242A1 (en) * 2020-03-02 2021-09-16 Heat Biologics, Inc. Immune-mediated coronavirus treatments
US20240409608A1 (en) * 2021-10-26 2024-12-12 Navicure Biopharmaceuticals Limited Combination therapies against cancer and infectious diseases
WO2025227519A1 (zh) * 2024-04-29 2025-11-06 北京臻知医学科技有限责任公司 一种肿瘤疫苗及其应用

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5217891A (en) 1987-07-28 1993-06-08 Chiron Corporation DNA constructs containing a kluyveromyces α factor leader sequence for directing secretion of heterologous polypeptides
CA1338778C (en) 1988-06-15 1996-12-10 Richard A. Young Stress proteins and uses therefor
WO1990002564A1 (en) 1988-09-12 1990-03-22 Codon Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi
US5232833A (en) 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
EP0484440A4 (en) 1989-07-28 1993-01-07 Us Health Efficient directional genetic cloning system
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
US5348945A (en) 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
US5188964A (en) 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
GB9016315D0 (en) 1990-07-25 1990-09-12 Burnie James P Medicaments
GB9024320D0 (en) 1990-11-08 1990-12-19 Univ London Treatment of uveitis
JPH06501479A (ja) 1990-11-08 1994-02-17 スタンフオード・ルツク・リミテツド 抗原担体
GB2251186A (en) 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
US5177942A (en) 1991-08-15 1993-01-12 The Toro Company Mower deck with improved belt drive arrangement
GB9200949D0 (en) 1992-01-17 1992-03-11 Medical Res Council Diagnostic peptides
FR2688227A1 (fr) 1992-03-04 1993-09-10 Inst Nat Sante Rech Med Proteines formant des complexes avec des chaperones et leurs ligands, leurs fragments, leur obtention et leurs applications biologiques.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
HUT70972A (en) 1992-03-09 1995-11-28 Ist Naz Stud Cura Dei Tumori Protein compound capable of inhibiting tumoral growth
WO1993021529A1 (en) 1992-04-14 1993-10-28 Duke University Method of detecting tumors containing complexes of p53 and hsp70
JPH07509694A (ja) 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
WO1994003599A1 (fr) 1992-08-04 1994-02-17 Sagami Chemical Research Center ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc
GB2270076A (en) 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
GB9223816D0 (en) 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
NZ263550A (en) 1993-03-19 1996-12-20 Boehringer Ingelheim Int Preparing cancer vaccines containing autologous tumour cells characterised in that tumour cells or firbroblasts are cultivated and transfected ex vivo with a composition of dna and a dna binding molecule conjugate
US5496934A (en) 1993-04-14 1996-03-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acids encoding a cellulose binding domain
US6004941A (en) 1993-06-14 1999-12-21 Basf Aktiengesellschaft Methods for regulating gene expression
WO1995004824A1 (en) 1993-08-05 1995-02-16 Medvet Science Pty. Ltd. Generation of dna libraries and retroviral vectors for same
US5705159A (en) 1993-08-31 1998-01-06 John Wayne Cancer Institute Immunoreactive peptide sequence from a 43 KD human cancer antigen
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
WO1996001611A1 (en) 1994-07-08 1996-01-25 Baxter International Inc. Implanted device containing tumor cells for the treatment of cancer
US5772995A (en) 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
JP3907698B2 (ja) 1994-10-03 2007-04-18 アメリカ合衆国 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
IL123219A0 (en) 1995-08-18 1998-09-24 Sloan Kettering Inst Cancer Method for treatment of cancer and infectious diseases and compositions useful in same
US6761892B1 (en) 1995-08-18 2004-07-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6719974B1 (en) 1995-08-18 2004-04-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6331299B1 (en) 1995-08-18 2001-12-18 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious disease and compositions useful in same
EP0851765A4 (en) 1995-09-13 2000-01-19 Univ Fordham THERAPEUTIC AND PROPHYLACTIC PROCESSES THAT USE HEAT SHOCK PROTEINS
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
DE19602985A1 (de) 1996-01-27 1997-07-31 Max Delbrueck Centrum Tumorzellimpfstoff für die Immuntheraphie von malignen Tumoren
WO1997026910A2 (de) 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumorimpfstoff für die immuntherapie von malignen tumoren
CA2249354A1 (en) 1996-03-28 1997-10-02 Genitrix, L.L.C. Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
US5747332A (en) 1996-09-20 1998-05-05 University Of New Mexico Methods for purifying and synthesizing heat shock protein complexes
US6130087A (en) 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
DK0941315T3 (da) 1996-11-26 2006-05-15 Stressgen Biotechnologies Corp Fusionsproteiner indeholdende stressproteiner til induktion af immunreaktioner
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6015709A (en) 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
DE69942810D1 (de) 1998-02-20 2010-11-11 Univ Miami Modifizierter Hitzeschockprotein-Antigenpeptid-Komplex
US5989910A (en) 1998-08-03 1999-11-23 University Of Lausanne Potent genetic switch allowing regulated gene expression in eukaryotic cells
US6797480B1 (en) 1998-10-05 2004-09-28 University Of Connecticut Health Center Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents
US6451316B1 (en) 1998-10-05 2002-09-17 University Of Conneticut Health Center Methods for generating antigen-reactive T cells in vitro
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
US6734172B2 (en) * 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
CA2362126C (en) * 1999-02-03 2017-01-17 Amgen Inc. B7rp-1 polypeptides
CN101070540B (zh) * 2000-04-28 2015-04-01 约翰霍普金斯大学 新的树突状细胞共刺激分子
US7132109B1 (en) 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
CA2452517A1 (en) 2001-07-11 2003-01-23 University Of Miami Recombinant vsv for the treatment of tumor cells
JP4384489B2 (ja) * 2001-08-20 2009-12-16 ユニバーシティー オブ コネティカット ヘルス センター 癌及び感染性疾患の治療に有用な熱ショックタンパク質又はα−２−マクログロブリンを含む組成物の調製方法
ATE435655T1 (de) * 2001-10-09 2009-07-15 Mayo Foundation Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort
EP1456376A4 (en) 2001-11-16 2006-09-06 Us Gov Health & Human Serv NEW CHIMERAL REV, TAT AND NEF ANTIGENES
WO2003057171A2 (en) * 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US20030170756A1 (en) 2002-02-01 2003-09-11 Thomas Jefferson University Treatment of tumor cells for use in immunotherapy of cancer
CN1440812A (zh) * 2002-02-27 2003-09-10 上海中信国健药业有限公司 一种使用cd137结合激动剂增强免疫应答的方法
WO2003072595A2 (en) * 2002-02-28 2003-09-04 Antigenics Inc. Methods and products based on oligomerization of stress proteins
IL164376A0 (en) * 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
AU2003231098A1 (en) * 2002-04-25 2003-11-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US6984389B2 (en) * 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
CA2489004C (en) * 2002-06-13 2013-01-08 Crucell Holland B.V. Agonistic binding molecules to the human ox40 receptor
WO2004032865A2 (en) 2002-10-09 2004-04-22 Central Iowa Health System Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
AU2004274430A1 (en) * 2003-09-12 2005-03-31 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
US20070141666A1 (en) 2003-09-26 2007-06-21 Applied Research Systems Ars Holding N.V. Leader sequences for use in production of proteins
EP1667701A4 (en) 2003-09-26 2007-02-14 Univ Miami TUMOR VACCINE
CA2548347A1 (en) * 2003-12-11 2005-06-30 Sidney Kimmel Cancer Center Methods for generating immunity to antigen
FR2867982B1 (fr) 2004-03-26 2007-07-20 Jean Marie Andrieu Procede pour amplifier l'activite de vaccins therapeutiques
WO2005124346A1 (en) * 2004-05-17 2005-12-29 The Board Of Trustees Of The University Of Illinois 4-1bb receptors are expressed on regulatory t-cells
EP2243788A1 (en) 2005-02-24 2010-10-27 Medical Research Council HIVCON: An HIV immunogen and uses thereof
EP2650020B1 (en) * 2005-05-06 2016-08-24 Providence Health & Services - Oregon Trimeric OX40-immunoglobulin fusion protein and methods of use
CA2621083C (en) * 2005-08-30 2017-04-11 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins
CA2652599C (en) * 2006-05-03 2019-09-24 Ross Kedl Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
WO2008108808A2 (en) * 2006-08-24 2008-09-12 Trustees Of Boston University Complexes derived from heterohybrid cells and uses thereof
PT2856876T (pt) * 2007-03-30 2018-03-28 Memorial Sloan Kettering Cancer Center Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos
ITPD20070252A1 (it) * 2007-07-24 2009-01-25 Primiero Paolo Complessi di grp94 ed immunoglobuline g umane
US9408909B2 (en) * 2007-09-14 2016-08-09 Vrije Universiteit Brussel Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
GB0719509D0 (en) * 2007-10-05 2007-11-14 Isis Innovation Molecular adjuvant
US8475785B2 (en) 2008-03-03 2013-07-02 The University Of Miami Allogeneic cancer cell-based immunotherapy
AU2009223784A1 (en) * 2008-03-08 2009-09-17 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
US8968720B2 (en) 2008-03-20 2015-03-03 University Of Miami Heat shock protein GP96 vaccination and methods of using same
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
CN102223894A (zh) 2008-11-21 2011-10-19 迈阿密大学 用于产生粘膜和系统免疫的hiv/siv疫苗
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
CA2757524A1 (en) * 2009-04-03 2010-10-07 Agenus Inc. Methods for preparing and using multichaperone-antigen complexes
JP5883384B2 (ja) * 2009-08-13 2016-03-15 ザ ジョンズ ホプキンス ユニバーシティー 免疫機能を調節する方法
US9459246B2 (en) 2009-09-08 2016-10-04 Nodality, Inc. Induced intercellular communication
CA2775761C (en) * 2009-09-30 2018-08-28 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
JP2013527753A (ja) * 2010-03-23 2013-07-04 イントレキソン コーポレーション 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用
US8828944B2 (en) 2010-04-22 2014-09-09 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
US9527912B2 (en) * 2010-05-17 2016-12-27 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
CA2837059A1 (en) 2010-05-21 2011-11-24 University Of Miami Cancer treatment
US9234042B2 (en) * 2010-10-18 2016-01-12 Delphi Genetics Sa Method for producing antibody using “naked” expression vector expressing type II transmembrane fusion protein
CN102462841A (zh) * 2010-11-09 2012-05-23 中国科学院微生物研究所 一种促进gp96蛋白的免疫活性的方法及其应用
JP2014508762A (ja) * 2011-02-23 2014-04-10 ユニバーシティー オブ マイアミ ＳＩＶ／ＨＩＶからの防御を目的とする、組合せ細胞ベースのｇｐ９６−Ｉｇ−ＳＩＶ／ＨＩＶ、組換えｇｐ１２０タンパク質のワクチン接種
WO2012166617A2 (en) 2011-05-27 2012-12-06 Cytocure Llc Methods, compositions, and kits for the treatment of cancer
SG11201404677TA (en) * 2011-12-12 2014-11-27 Cell Medica Ltd Process of expanding t cells
US9567606B2 (en) * 2012-02-14 2017-02-14 Merial Inc. Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom
DK2925350T3 (da) * 2012-12-03 2019-05-13 Bristol Myers Squibb Co Øgning af virksomheden mod cancer af immunomodulatoriske fc- fusionsproteiner
ES2689080T3 (es) * 2013-01-02 2018-11-08 Glenmark Pharmaceuticals S.A. Anticuerpos que se unen a TL1A y sus usos
US20140193410A1 (en) * 2013-01-09 2014-07-10 University Of Miami Compositions and Methods for the Regulation of T Regulatory Cells Using TL1A-Ig Fusion Protein
EP2951209A4 (en) * 2013-01-31 2016-06-22 Univ Jefferson CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF
CA2906356A1 (en) 2013-03-15 2014-09-18 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
WO2014140884A2 (en) 2013-03-15 2014-09-18 Novelogics Biotechnology, Inc. Methods and devices for removal of immunosuppressive ligands
US10196435B2 (en) * 2013-11-18 2019-02-05 University Of Southern California OX40L fusion protein for the immunotherapy of tumors of veterinary animals
CA2931322A1 (en) * 2013-11-22 2015-05-28 Dnatrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
EP3082853A2 (en) * 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
WO2015131176A1 (en) * 2014-02-28 2015-09-03 Podack Eckhard R Compositions, methods, and kits for treatment of cancer
KR20170002410A (ko) * 2014-04-03 2017-01-06 오거스타 유니버시티 리서치 인스티튜트, 인크. 종양 유도 면역 반응의 효능을 향상시키는 방법
BR112016027845A2 (pt) * 2014-05-29 2017-10-31 Medimmune Llc proteínas de fusão de ox40l e usos das mesmas
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
MA41460A (fr) * 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
SG11201705844SA (en) * 2015-02-06 2017-08-30 Heat Biologics Inc Vector co-expressing vaccine and costimulatory molecules
TWI716405B (zh) * 2015-05-07 2021-01-21 美商艾吉納斯公司 抗ox40抗體及其使用方法
CN109219620B (zh) * 2016-06-09 2023-01-31 派立卡恩治疗公司 抗-tnfrsf25抗体
CA3058938A1 (en) * 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
WO2019104327A1 (en) * 2017-11-27 2019-05-31 Heat Biologics, Inc. Gp96-based cancer therapy
EP3860647A4 (en) * 2018-10-01 2022-10-19 Heat Biologics, Inc. CELL-BASED COMBINATION THERAPIES
EP4019536A4 (en) * 2019-08-19 2023-09-06 Nantong Yichen Biopharma. Co. Ltd. IMMUNOCYTOTIN, ITS PRODUCTION AND ITS USE
US20210283242A1 (en) * 2020-03-02 2021-09-16 Heat Biologics, Inc. Immune-mediated coronavirus treatments

Also Published As

Publication number Publication date
BR112017016681A2 (pt) 2018-04-10
CA2975191C (en) 2023-05-09
EP3253876A4 (en) 2018-09-19
AU2016215175A1 (en) 2017-09-21
AU2016215175B2 (en) 2021-09-16
US10046047B2 (en) 2018-08-14
WO2016127015A1 (en) 2016-08-11
JP6744318B2 (ja) 2020-08-26
RU2714157C2 (ru) 2020-02-12
CN107208099A (zh) 2017-09-26
CA2975191A1 (en) 2016-08-11
US20180360955A1 (en) 2018-12-20
CN107208099B (zh) 2022-05-13
RU2017127025A (ru) 2019-03-07
IL253423B (en) 2021-08-31
SG11201705844SA (en) 2017-08-30
EP3253876B1 (en) 2020-11-04
RU2017127025A3 (enExample) 2019-07-17
EP3253876A1 (en) 2017-12-13
MX2017010159A (es) 2017-12-18
IL253423A0 (en) 2017-09-28
ES2845727T3 (es) 2021-07-27
US10758611B2 (en) 2020-09-01
DK3253876T3 (da) 2021-01-25
US20210000945A1 (en) 2021-01-07
MX384422B (es) 2025-03-14
US20190000967A1 (en) 2019-01-03
US20160250322A1 (en) 2016-09-01
US10780161B2 (en) 2020-09-22
JP2018509888A (ja) 2018-04-12
HK1247960A1 (zh) 2018-10-05

Similar Documents

Publication Publication Date Title
CN107208099B (zh) 共表达疫苗和共刺激分子的载体
US20200308238A1 (en) Heterodimeric proteins for modulating gamma delta t cells
US20230303659A1 (en) Intratumoral vaccination
US20210046177A1 (en) Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
JP2022516964A (ja) ガンマデルタｔ細胞を調節するためのヘテロ二量体タンパク質
US20210346486A1 (en) Combination cell-based therapies
KR20200092964A (ko) Gp96-기반 암 치료법
US20220298252A1 (en) Methods of treating cancer using tnfrsf25 antibodies
HK1247960B (en) Vector co-expressing vaccine and costimulatory molecules

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170808

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210203

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230424

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230705

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230424

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I